Skip to main
  1. Stocks
  2. 10X Genomics
  3. Forecast
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 21%
Buy 14%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is supported by a strong revenue trajectory, with 2028E revenue raised to $732.5M and EPS improved to -$0.40, signaling better operating leverage and closer progression toward profitability. Its outlook is underpinned by durable consumables demand and recurring platform usage across Chromium, Visium, and Xenium, which should support scale as installed instruments continue to drive follow-on sales. The company also has a solid balance sheet with $523M in cash versus $84M in debt, giving it flexibility to invest in growth and absorb volatility while aligning valuation with a 7.7x 2028E EV/revenue multiple.

Bears say

10x Genomics is facing a negative outlook because the latest reported production and sales figures came in below expectations, signaling execution risk and weaker near-term operating momentum. Q2/26 consolidated AuEq production of 96,297 oz and sales of 91,646 oz missed the 105.8 koz estimate, while gold, copper, and silver output also trailed consensus as Media Luna moved through planned lower-grade, lower-recovery areas. Although 2026 guidance of 420–470 koz AuEq was reiterated, YTD output of 197,171 oz produced and 200,868 oz sold points to reliance on a second-half grade improvement, leaving the investment case dependent on a timely operational ramp and a 2026 first-ore milestone.

10X Genomics (TXG) has been analyzed by 14 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 14% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

10X Genomics (TXG) Analyst Forecast & Price Prediction

Get the latest 10X Genomics (TXG) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in 10X Genomics (TXG)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Buy based on their latest research and market trends.

According to 14 analysts, 10X Genomics (TXG) has a Buy consensus rating as of Nov 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $72.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $72.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


10X Genomics (TXG) Analyst Forecast & Price Prediction

Get the latest 10X Genomics (TXG) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in 10X Genomics (TXG)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover TXG stock data and trends